This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Richard Saintvilus


Richard Saintvilus is the founder and CEO of After 20 successful years in the IT industry, Richard Saintvilus decided his second act would be as a stock analyst -- bringing logic from an investor's point of view. His goal is to remove the complicated aspect of investing and present it to readers in a way that makes sense. Richard's work has been featured on CNBC, Yahoo! Finance, MSN Money, Forbes, Motley Fool and numerous other outlets.

Richard Saintvilus
By This Author:
Page 2 of 104

Johnson & Johnson Should Ignore Those Breakup Calls

By Richard Saintvilus

Who cares about J&J's sluggish medical devices business when it has such a strong drug pipeline and balance sheet?

06:30AM 09/09/14

Bristol-Myers Needs a Healthy Growth Shot to Justify Its Valuation

By Richard Saintvilus

These shares are still too expensive for new investors.

06:00AM 09/09/14

Why Valeant's Hostile Takeover Bid of Allergan Is Bad for Shareholders

By Richard Saintvilus

Allergan's management and its board are right to resist Bill Ackman's bid and protect the interest of shareholders.

06:30AM 09/08/14

Why Baxter International Offers Great Reward for Minimal Risk

By Richard Saintvilus

Wall Street is wrong to discount Baxter's value-creating potential.

06:00AM 09/08/14

Novartis Offers Healthy Gains at a Bargain Stock Price

By Richard Saintvilus

The company has a potential life-saving catalyst in its portfolio, too.

06:30AM 09/05/14

Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential

By Richard Saintvilus

There's no compelling reason to buy this stock above $40.

06:00AM 09/05/14

Splunk Investors Still in a Funk Despite Strong Revenue Growth

By Richard Saintvilus

The market seems divided on where the company is heading next.

06:30AM 09/04/14

Pricey Stryker Needs a Deal to Spur Healthy Growth

By Richard Saintvilus

Stryker needs a new set of offerings that allows it to differentiate from peers that are trading at a much lower multiple.

06:00AM 09/04/14

Red Hat CEO Jim Whitehurst: We're Ready to Dominate the Cloud

By Richard Saintvilus

With Red Hat's long history of open source expertise, the company is in position to dominate its market for years to come.

06:00AM 09/03/14

Why Endo International Can Deliver Solid Rewards With Minimal Risk

By Richard Saintvilus

With the recent deal for DAVA, Endo is now one of the best health care stocks to own.

02:31PM 09/02/14

Page 2 of 104

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs